Role of definitive chemoradiotherapy using docetaxel and 5‐fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study. Issue 8 (15th October 2015)

• Record Type: Journal Article
• Authors: Hihara, J.; Hamai, Y.; Emi, M.; Murakami, Y.; Kenjo, M.; Nagata, Y.; Okada, M.
• Is Part Of: Diseases of the esophagus. Volume 29:Issue 8(2016)
• Page Start: 1115
• Page End: 1120
• Publication Date: 2015-10-15
• Subjects: 5‐fluorouracil -- concurrent chemoradiotherapy -- docetaxel -- esophageal cancer -- renal dysfunction; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1111/dote.12433
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: Definitive chemoradiotherapy (CRT) with docetaxel (DOC) and 5‐fluorouracil (5‐FU) is a unique regimen for esophageal cancer. In this prospective phase II study, antitumor effect and safety of CRT using DOC and 5‐FU for inoperable locally advanced esophageal cancer were evaluated. DOC 7.5 mg/m 2 was infused on days 1, 8, 22, and 29. 5‐FU 250 mg/m 2 /day was infused continuously on days 1–5, 8–12, 15–19, 22–26, 29–33, 36–40, and 43–45. Radiotherapy was given to 66 Gy in 33 fractions. Eleven patients with thoracic and five with cervical esophageal cancer were eligible. All patients had esophageal squamous cell carcinoma (ESCC). The response rate was 94%, with complete response in five patients (31%) and partial response in 10 (63%). Hematologic toxicity was mild; only one patient (6%) had Grade 1 leukopenia. Nonhematologic Grade 3 or higher adverse events were esophagitis (31%), anorexia (6%), and esophago‐bronchial fistula (6%). No treatment‐related deaths occurred. The median time to progression was 20 months and overall 3‐year and 5‐year survival were 44% and 31%, respectively. Definitive CRT using DOC and 5‐FU could be performed safely, and it demonstrated a favorable antitumor effect for ESCC. This regimen might be indicated in patients in whom it is desirable to avoid myelosuppression and progression of renal impairment.